NCT00227435View on ClinicalTrials.gov

Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

February 28, 2003

Primary Completion Date

July 31, 2004

Study Completion Date

July 31, 2004

Conditions
Chronic Hepatitis C
Interventions
DRUG

val-mCyd

Trial Locations (4)

Unknown

Pasadena

Boston

Worcester

Fairfax

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00227435 - Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C | Biotech Hunter | Biotech Hunter